FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

René Levy

Research Profile

Chemicals & Drugs

Physiology

Disorders

Anatomy

Living Beings

Rats

Concepts & Ideas

Co-author Network

Publications

TOP 3
Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI).
Gretchen L Birbeck; David B Clifford; Henry Fraimow; Jacqueline A French; Jomy M George; Houda Hachad; René H Levy; Jason F Okulicz; Emilio Perucca; David M Simpson
Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN.
C K Yeung; René H Levy; Y Fujioka; Houda Hachad; Nina Isoherranen
Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of René Levy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI).
Epilepsy research 2013;103(1):2-30.
2012: Gretchen L Birbeck; David B Clifford; Henry Fraimow; Jacqueline A French; Jomy M George; Houda Hachad; René H Levy; Jason F Okulicz; Emilio Perucca; David M Simpson
Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN.
Epilepsia 2012;53(1):207-14.
2011: C K Yeung; René H Levy; Y Fujioka; Houda Hachad; Nina Isoherranen
Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.
Clinical pharmacology and therapeutics 2011;89(1):105-13.
2010: Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).
Epilepsy research 2010;92(2-3):89-124.
2010: Houda Hachad; Isabelle Ragueneau-Majlessi; René H Levy
A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database.
Human genomics 2010;5(1):61-72.
2009: Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H White
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).
Epilepsy research 2009;83(1):1-43.
2007: Isabelle Ragueneau-Majlessi; Xavier Boulenc; Clemence Rauch; Houda Hachad; René H Levy
Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.
Current drug metabolism 2007;8(8):810-4.
2007: René H Levy; Carol Collins
Risk and predictability of drug interactions in the elderly.
International review of neurobiology 2007;81():235-51.
2007: Meir Bialer; Svein I Johannessen; Harvey J Kupferberg; René H Levy; Emilio Perucca; Torbjörn Tomson
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).
Epilepsy research 2007;73(1):1-52.
2005: Dorit Mimrod; Luigi Maria Specchio; Malka Britzi; Emilio Perucca; Nicola Specchio; Angela La Neve; Stefan Soback; René H Levy; Giuliana Gatti; Dennis R Doose; Bruce E Maryanoff; Meir Bialer
A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy.
Epilepsia 2005;46(7):1046-54.
2005: René H Levy; Isabelle Ragueneau-Majlessi; Martin J Brodie; David F Smith; Jaymin Shah; Wei-Jian Pan
Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy.
Therapeutic drug monitoring 2005;27(2):193-8.
2005: Malka Britzi; Emilio Perucca; Stefan Soback; René H Levy; Cinzia Fattore; Francesca Crema; Giuliana Gatti; Dennis R Doose; Bruce E Maryanoff; Meir Bialer
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine.
Epilepsia 2005;46(3):378-84.
2005: Isabelle Ragueneau-Majlessi; René H Levy; Martin Brodie; David Smith; Jaymin Shah; John S Grundy
Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.
Clinical pharmacokinetics 2005;44(5):517-23.
2004: Isabelle Ragueneau-Majlessi; René H Levy; Donna Bergen; William Garnett; William Rosenfeld; Gary Mather; Jaymin Shah; John S Grundy
Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients.
Epilepsy research 2004;62(1):1-11.
2004: René H Levy; Isabelle Ragueneau-Majlessi; William R Garnett; Michael Schmerler; William Rosenfeld; Jaymin Shah; Wei-Jian Pan
Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy.
Journal of clinical pharmacology 2004;44(11):1230-4.
2004: Meir Bialer; Svein I Johannessen; Harvey J Kupferberg; René H Levy; Emilio Perucca; Torbjörn Tomson
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).
Epilepsy research 2004;61(1-3):1-48.
2004: Nina Isoherranen; René H Levy; Boris Yagen; José H Woodhead; H White; Meir Bialer
Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites.
Epilepsy research 2004;58(1):1-12.
2003: René H Levy; Houda Hachad; C Yao; Isabelle Ragueneau-Majlessi
Relationship between extent of inhibition and inhibitor dose: literature evaluation based on the metabolism and transport drug interaction database.
Current drug metabolism 2003;4(5):371-80.
2003: John M Neal; Kent L Kunze; René H Levy; Robert A O'Reilly; William F Trager
Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(8):1043-8.
2003: Malka Britzi; Stefan Soback; Nina Isoherranen; René H Levy; Emilio Perucca; Dennis R Doose; Bruce E Maryanoff; Meir Bialer
Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay.
Therapeutic drug monitoring 2003;25(3):314-22.
2003: Caiping Yao; Kent L Kunze; William F Trager; Evan D Kharasch; René H Levy
Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(5):565-71.
2003: Jyoti Chawla; Marie-Emmanuelle Le Guern; Christine Alquier; Thomas F Kalhorn; René H Levy
Effect of route of administration on the pharmacokinetic behavior of enantiomers of nefopam and desmethylnefopam.
Therapeutic drug monitoring 2003;25(2):203-10.
2002: F Lakehal; colleen johnson wurden; Thomas F Kalhorn; René H Levy
Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.
Epilepsy research 2002;52(2):79-83.
2002: Meir Bialer; Svein I Johannessen; Harvey J Kupferberg; René H Levy; P Loiseau; Emilio Perucca
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).
Epilepsy research 2002;51(1-2):31-71.
2002: Caiping Yao; René H Levy
Inhibition-based metabolic drug-drug interactions: predictions from in vitro data.
Journal of pharmaceutical sciences 2002;91(9):1923-35.
2002: Isabelle Ragueneau-Majlessi; René H Levy; Franz Janik
Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women.
Epilepsia 2002;43(7):697-702.
2002: R C Sachdeo; S K Sachdeo; René H Levy; Anthony J Streeter; FE Bishop; K L Kunze; Gary Mather; Lorin K Roskos; Danny D Shen; K E Thummel; William F Trager; Christopher Curtin; Dennis R Doose; LG Gisclon; Meir Bialer
Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
Epilepsia 2002;43(7):691-6.
2002: Houda Hachad; Isabelle Ragueneau-Majlessi; René H Levy
New antiepileptic drugs: review on drug interactions.
Therapeutic drug monitoring 2002;24(1):91-103.
2001: Caiping Yao; Kent L Kunze; Evan D Kharasch; Y Wang; William F Trager; I Ragueneau; René H Levy
Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.
Clinical pharmacology and therapeutics 2001;70(5):415-24.
2001: Isabelle Ragueneau-Majlessi; René H Levy; C Meyerhoff
Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.
Epilepsy research 2001;47(1-2):55-63.
2001: René H Levy; Isabelle Ragueneau-Majlessi; E Baltes
Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers.
Epilepsy research 2001;46(2):93-9.
2001: Meir Bialer; Svein I Johannessen; Harvey J Kupferberg; René H Levy; P Loiseau; Emilio Perucca
Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V).
Epilepsy research 2001;43(1):11-58.
2000: XY Wang; René H Levy; Rodney J Y Ho
Development of a semi-quantitative assay to detect full-length CYP2C19 RNA.
BioTechniques 2000;29(2):364-70, 372-3.
2000: Gary Mather; RB Labroo; Marie-Emmanuelle Le Guern; F Lepage; JM Gillardin; René H Levy
Nefopam enantiomers: preclinical pharmacology/toxicology and pharmacokinetic characteristics in healthy subjects after intravenous administration.
Chirality 2000;12(3):153-9.
2000: Ofer Spiegelstein; D L Kroetz; René H Levy; Boris Yagen; S I Hurst; M Levi; Abdullah Haj-Yehia; Meir Bialer
Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid.
Pharmaceutical research 2000;17(2):216-21.
1999: D A Erickson; Gary Mather; William F Trager; René H Levy; JJ Keirns
Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(12):1488-95.
1999: Ofer Spiegelstein; Boris Yagen; René H Levy; Richard Finnell; Gregory D Bennett; Michael Roeder; Volker Schurig; Meir Bialer
Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.
Pharmaceutical research 1999;16(10):1582-8.
1999: C P Yao; Gary Mather; J R Stephens; René H Levy
Cytotoxicity induced by the combination of valproic acid and tumor necrosis factor-alpha: implication for valproic acid-associated hepatotoxicity syndrome.
Biochemical pharmacology 1999;58(3):455-9.
1999: Allan E Rettie; Robert L Haining; M Bajpai; René H Levy
A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.
Epilepsy research 1999;35(3):253-5.
1999: Richard Finnell; Gregory D Bennett; Gary Mather; Bogdan Wlodarczyk; M Bajpai; René H Levy
Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model.
Reproductive toxicology (Elmsford, N.Y.) 1999;13(2):85-91.
1999: Meir Bialer; Svein I Johannessen; Harvey J Kupferberg; René H Levy; P Loiseau; Emilio Perucca
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV).
Epilepsy research 1999;34(1):1-41.
1998: Meir Bialer; René H Levy; Emilio Perucca
Does carbamazepine have a narrow therapeutic plasma concentration range?
Therapeutic drug monitoring 1998;20(1):56-9.
1998: René H Levy; Gary Mather
Metabolic enzymes and antiepileptic drug interactions.
Advances in neurology 1998;76():49-55.
1997: Joel Morganroth; WH Lyness; JL Perhach; Gary Mather; J E Harr; William F Trager; René H Levy; A Rosenberg
Lack of effect of azelastine and ketoconazole coadministration on electrocardiographic parameters in healthy volunteers.
Journal of clinical pharmacology 1997;37(11):1065-72.
1997: Agnès Tran; Elisabeth Rey; Gérard Pons; M Rousseau; Philippe d'Athis; Georges Olive; Gary Mather; FE Bishop; colleen johnson wurden; RB Labroo; William F Trager; Kent L Kunze; Kenneth E Thummel; J C Vincent; JM Gillardin; F Lepage; René H Levy
Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.
Clinical pharmacology and therapeutics 1997;62(5):490-504.
1997: Paul Glue; Christopher Banfield; JL Perhach; Gary Mather; J K Racha; René H Levy
Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.
Clinical pharmacokinetics 1997;33(3):214-24.
1997: S W Martin; FE Bishop; B M Kerr; M Moor; M Moore; Pamela Sheffels; M Rashed; J Greg Slatter; L Berthon-Cédille; F Lepage; J J Descombe; M Picard; Thomas A Baillie; René H Levy
Pharmacokinetics and metabolism of the novel anticonvulsant agent N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide (D2624) in rats and humans.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(1):40-6.
1996: M Bajpai; Lorin K Roskos; Danny D Shen; René H Levy
Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(12):1401-3.
1996: Meir Bialer; S I Johannessen; Harvey J Kupferberg; René H Levy; P Loiseau; E Perucca
Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference.
Epilepsy research 1996;25(3):299-319.
1996: Gail D Anderson; M K Yau; B E Gidal; S J Harris; René H Levy; A A Lai; K B Wolf; W A Wargin; A T Dren
Bidirectional interaction of valproate and lamotrigine in healthy subjects.
Clinical pharmacology and therapeutics 1996;60(2):145-56.
1996: Gary Mather; René H Levy
Pharmacokinetics of polypharmacy: prediction of drug interactions.
Epilepsy research. Supplement 1996;11():113-21.
1995: J P Stables; Meir Bialer; S I Johannessen; Harvey J Kupferberg; René H Levy; P Loiseau; E Perucca
Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference.
Epilepsy research 1995;22(3):235-46.
1995: René H Levy
Cytochrome P450 isozymes and antiepileptic drug interactions.
Epilepsia 1995;36 Suppl 5():S8-13.
1994: C Tang; K Zhang; F Lepage; René H Levy; Thomas A Baillie
Metabolic chiral inversion of stiripentol in the rat. II. Influence of route of administration.
Drug metabolism and disposition: the biological fate of chemicals 1994;22(4):554-60.
1994: K Zhang; C Tang; M Rashed; D Cui; F Tombret; H Botte; F Lepage; René H Levy; Thomas A Baillie
Metabolic chiral inversion of stiripentol in the rat. I. Mechanistic studies.
Drug metabolism and disposition: the biological fate of chemicals 1994;22(4):544-53.
1994: B M Kerr; K E Thummel; colleen johnson wurden; S M Klein; D L Kroetz; F J Gonzalez; René H Levy
Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation.
Biochemical pharmacology 1994;47(11):1969-79.
1994: R H Arends; K Zhang; René H Levy; Thomas A Baillie; Danny D Shen
Stereoselective pharmacokinetics of stiripentol: an explanation for the development of tolerance to anticonvulsant effect.
Epilepsy research 1994;18(2):91-6.
1994: Gail D Anderson; A A Acheampong; René H Levy
Interaction between valproate and branched-chain amino acid metabolism.
Neurology 1994;44(4):742-4.
1994: J R Stephens; René H Levy
Effects of valproate and citrulline on ammonium-induced encephalopathy.
Epilepsia 1994;35(1):164-71.
1993: S M Klein; Gary W Elmer; Lynne V McFarland; Christina M Surawicz; René H Levy
Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers.
Pharmaceutical research 1993;10(11):1615-9.
1993: D L Kroetz; P Loiseau; M Guyot; René H Levy
In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide.
Clinical pharmacology and therapeutics 1993;54(5):485-97.
1993: J R Farwell; Gail D Anderson; B M Kerr; J A Tor; René H Levy
Stiripentol in atypical absence seizures in children: an open trial.
Epilepsia 1993;34(2):305-11.
1993: D L Kroetz; B M Kerr; L V McFarland; P Loiseau; Alan J Wilensky; René H Levy
Measurement of in vivo microsomal epoxide hydrolase activity in white subjects.
Clinical pharmacology and therapeutics 1993;53(3):306-15.
1992: Gail D Anderson; René H Levy
The effect of valproate on the metabolism of phenobarbital in the rat.
Pharmaceutical research 1992;9(12):1622-8.
1992: Gail D Anderson; A A Acheampong; Alan J Wilensky; René H Levy
Effect of valproate dose on formation of hepatotoxic metabolites.
Epilepsia 1992;33(4):736-42.
1992: J R Stephens; René H Levy
Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.
Pharmaceutisch weekblad. Scientific edition 1992;14(3A):118-21.
1992: Danny D Shen; René H Levy; J L Savitch; A V Boddy; F Tombret; F Lepage
Comparative anticonvulsant potency and pharmacokinetics of (+)-and (-)-enantiomers of stiripentol.
Epilepsy research 1992;12(1):29-36.
1992: Danny D Shen; George A Ojemann; R L Rapport; Russell L Dills; P N Friel; René H Levy
Low and variable presence of valproic acid in human brain.
Neurology 1992;42(3 Pt 1):582-5.
1991: A V Boddy; Gary W Elmer; Lynne V McFarland; René H Levy
Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats.
Pharmaceutical research 1991;8(6):796-800.
1991: A V Boddy; K Zhang; F Lepage; F Tombret; J Greg Slatter; Thomas A Baillie; René H Levy
In vitro and in vivo investigations of dihydropyridine-based chemical delivery systems for anticonvulsants.
Pharmaceutical research 1991;8(6):690-7.
1991: René H Levy; A V Boddy
Stereoselectivity in pharmacokinetics: a general theory.
Pharmaceutical research 1991;8(5):551-6.
1991: B M Kerr; J M Martinez-Lage; C Viteri; J Tor; A C Eddy; René H Levy
Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol.
Epilepsia 1991;32(2):267-74.
1990: Danny D Shen; René H Levy; M J Moor; J L Savitch
Efficacy of stiripentol in the intravenous pentylenetetrazol infusion seizure model in the rat.
Epilepsy research 1990;7(1):40-8.
1990: René H Levy; A W Rettenmeier; Gail D Anderson; Alan J Wilensky; P N Friel; Thomas A Baillie; A Acheampong; J Tor; M Guyot; P Loiseau
Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid.
Clinical pharmacology and therapeutics 1990;48(3):225-35.
1990: B M Kerr; René H Levy
Unsubstituted amides: new class of potent inhibitors of human microsomal epoxide hydrolase.
Drug metabolism and disposition: the biological fate of chemicals 1990;18(4):540-2.
1989: K M Koch; K S Prickett; A W Rettenmeier; Thomas A Baillie; René H Levy
Beta-oxidation of valproate. II. Effects of fasting, glucose, and clofibrate in rats.
Epilepsia 1989;30(6):790-6.
1989: K M Koch; Alan J Wilensky; René H Levy
Beta-oxidation of valproic acid. I. Effects of fasting and glucose in humans.
Epilepsia 1989;30(6):782-9.
1989: M J Moor; M S Rashed; Thomas F Kalhorn; René H Levy; William N Howald
Application of thermospray liquid chromatography-mass spectrometry to the simultaneous quantification of tracer concentrations of isotopically labelled carbamazepine epoxide and steady-state levels of carbamazepine and carbamazepine epoxide.
Journal of chromatography 1989;474(1):223-30.
1989: B M Kerr; Allan E Rettie; A C Eddy; P Loiseau; M Guyot; Alan J Wilensky; René H Levy
Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation.
Clinical pharmacology and therapeutics 1989;46(1):82-93.
1989: A W Rettenmeier; William N Howald; René H Levy; D J Witek; W P Gordon; D J Porubek; Thomas A Baillie
Quantitative metabolic profiling of valproic acid in humans using automated gas chromatographic/mass spectrometric techniques.
Biomedical & environmental mass spectrometry 1989;18(3):192-9.
1989: P N Friel; George A Ojemann; R L Rapport; René H Levy; G Van Belle
Human brain phenytoin: correlation with unbound and total serum concentrations.
Epilepsy research 1989;3(1):82-5.
1989: René H Levy; B M Kerr
Pharmacokinetics of old, new, and yet-to-be-discovered antiepileptic drugs.
Epilepsia 1989;30 Suppl 1():S35-41; discussion S64-8.
1988: J S Lockard; René H Levy
Carbamazepine plus stiripentol: is polytherapy by design possible?
Epilepsia 1988;29(4):476-81.
1988: René H Levy; B M Kerr
Clinical pharmacokinetics of carbamazepine.
The Journal of clinical psychiatry 1988;49 Suppl():58-62.
1986: T A Moreland; J Astoin; F Lepage; F Tombret; René H Levy; Thomas A Baillie
The metabolic fate of stiripentol in man.
Drug metabolism and disposition: the biological fate of chemicals 1986;14(6):654-62.
1986: A W Rettenmeier; W P Gordon; K S Prickett; René H Levy; Thomas A Baillie
Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
Drug metabolism and disposition: the biological fate of chemicals 1986;14(4):454-64.
1986: A W Rettenmeier; W P Gordon; K S Prickett; René H Levy; J S Lockard; K E Thummel; Thomas A Baillie
Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid.
Drug metabolism and disposition: the biological fate of chemicals 1986;14(4):443-53.
1985: A W Rettenmeier; K S Prickett; W P Gordon; S M Bjorge; S L Chang; René H Levy; Thomas A Baillie
Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates.
Drug metabolism and disposition: the biological fate of chemicals 1985;13(1):81-96.
1982: J S Lockard; René H Levy; L L DuCharme; W C Congdon
EEG quantification of drug level effects in monkey model of partial epilepsy.
Electroencephalography and clinical neurophysiology. Supplement 1982;36():487-503.
1980: J S Lockard; René H Levy; L L DuCharme; W C Congdon
Cinromide's metabolite in monkey model: gastric administration and seizure control.
Epilepsia 1980;21(2):177-82.